#United States #South San Francisco #Dualitas Therapeutics #Karim Dabbagh #DTX-102

Leadership Change at Dualitas Therapeutics

Dualitas Therapeutics, a pioneering biotechnology firm, has appointed Dr. Karim Dabbagh as its new Chief Executive Officer. Dr. Dabbagh brings significant leadership experience in immunology, specifically relating to inflammation therapies and their advancement through clinical trials. His previous roles include being the President and CEO at Silver Creek Pharmaceuticals and Second Genome, where he notably advanced drug development and secured valuable collaborations.

Dualitas has strategically positioned itself at a crucial juncture, anticipating the clinical trials for its lead development candidate, DTX-102, to commence in 2027. DTX-102 is a groundbreaking bispecific antibody designed to leverage Dualitas' proprietary immune proximity engager technology for treating rheumatoid arthritis—and potentially other autoimmune diseases.

"This is a pivotal time for Dualitas, as we begin advancing our first differentiated bispecific antibody therapies into the clinic next year," commented Dr. Dabbagh. He emphasized that the technology not only has the potential to set a new efficacy standard in autoimmune treatments but also aims to address the needs of millions of patients currently underserved by existing therapies.

The unique aspect of Dualitas' technology lies in its approach to developing bispecific antibodies. Unlike conventional methods that attempt to combine two separate inhibitors, Dualitas utilizes a novel immune proximity engager that pairs synergistically with existing immune targets. This innovative combination is expected to yield amplified pharmacological responses that are far more effective than those produced by traditional monospecific agents.

Dualitas is applying this technology to numerous validated immune pathways, with DTX-102 aiming to capitalize on the CD28 pathway. Preclinical studies—both in vitro and in vivo—are showing significantly greater potency and longer-lasting immune modulation than currently approved therapies, marking a potential paradigm shift in treatment protocols.

In addition to DTX-102, Dr. Dabbagh announced two further programs utilizing their proprietary proximity engager technology during his introductory remarks. DTX-103 is designed as an anti-FcεRI bispecific antibody targeting the IgE pathway, potentially treating a range of allergic diseases such as chronic urticaria and asthma. Meanwhile, DTX-101 focuses on the IL-2Rβ pathway, which may have widespread implications for dermatological and gastrointestinal disorders.

The foundation for advancing these initiatives was significantly bolstered by Dualitas’ recent Series A financing round, which raised $65 million in September 2025. These funds are earmarked to support the clinical entry of DTX-102 and the ongoing development of its comprehensive portfolio.

Overall, Dr. Dabbagh’s leadership is expected to guide Dualitas Therapeutics through this evolutionary phase, with hopes set high for innovative breakthroughs in treating severe autoimmune conditions. The fusion of novel scientific approaches and experienced leadership could present a compelling narrative in the biotech landscape. As the clinical trials for DTX-102 draw closer, stakeholders within the industry are keenly aware that Dualitas may very well set new precedents in treatment effectiveness and patient care.

Stay tuned for further updates on Dualitas Therapeutics and its endeavors as they navigate this exciting era of biopharmaceutical innovation.